New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity 6th December, 2023: Teva Pharmaceuticals has announced that a post hoc analysis [iv] of two Phase 3 clinical studies presented at the European Headache Congress has shown the effectiveness of the migraine prevention treatment AJOVY®…
Category: Headache
Ubrelvy for migraine: positive phase III data
AbbVie recently announced its publication in The Lancet showing that administration of Ubrelvy (ubrogepant) during the prodrome stage of a migraine can reduce the likelihood of a migraine attack developing. Ubrelvy is the first and only acute migraine treatment that has demonstrated Phase III data in the prodrome stage. Christie Wong, Pharma Analyst at GlobalData,…
Are CGRP medications effective against migraine in men?
Via Medscape: Most patients with migraine are women. This female predominance is reflected in the clinic and in clinical trials, where ~85% are women. A pharmacologist and a neurologist from the United States argue that the efficacy of calcitonin gene-related peptide (CGRP)-based migraine therapies has been proven in women but not in men, and that men should be informed…
Reducing migraine in Major Depressive Disorder
Teva Phase IV UNITE study shows AJOVY® (fremanezumab) reduced migraine attacks and depression symptoms in migraine sufferers with Major Depressive Disorder 17th October, 2023: Teva Pharmaceutical Industries Ltd has announced that data from the UNITE study presented today at the World Congress of Neurology in Montreal, Canada, show that AJOVY® (fremanezumab) reduced migraine attacks and…
Real-world study on AJOVY® reveals sustained long-term effectiveness in migraine
Data presented at the European Academy of Neurology Congress 2023: Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine JULY 2023, TEL AVIV, Israel: Teva Pharmaceutical Industries Ltd has announced further positive data from…
Acute migraine treatment accepted for use on NHS in Scotland
9th May, 2023: Pfizer Ltd announced that the Scottish Medicines Consortium (SMC) has accepted Vydura ® (rimegepant) for restricted use for the treatment of acute migraine with or without aura, for patients who have had inadequate symptom relief after trials of at least two triptans or in whom triptans are contraindicated or not tolerated; and…
#AAN2023: Atogepant for preventive treatment of episodic migraine
21 April 2023: AbbVie has announced positive data from its Phase 3 ELEVATE study, evaluating atogepant for the preventive treatment of episodic migraine in people who had previously failed two to four classes of oral preventive medications. The results of the study demonstrated adult patients in the atogepant 60 mg once daily (QD) arm experienced…
Drug to lower brain pressure could treat blinding IIH headaches
March 13, 2023: Patients with ‘blinding’ headaches known as Idiopathic Intercranial Hypertension (IIH) could be treated with an injectable peptide used for type 2 diabetes, a new trial has found. The study, published in the journal Brain, reports on a phase two trial of a drug called exenatide, a GLP-1 receptor agonist, as a potential…
NICE approves eptinezumab (Vyepti) to treat episodic and chronic migraine
On 25th January 2023, the National Institute for Health and Care Excellence (NICE) announced that eptinezumab (Vyepti) has been approved for use within the NHS in England for the treatment of episodic migraine. Eptinezumab is given by infusion once every 12 weeks. It is one of a number of calcitonin gene-related peptide (CGRP) antibody drugs, which are…
